Clinical Trials & Research

A team of international scientists from Nanyang Technological University, Singapore (NTU Singapore), Tan Tock Seng Hospital (TTSH) in Singapore, and the Massachusetts Institute of Technology (MIT) has developed a simple method of extracting tiny biological particles from a person’s blood and use them as biomarkers to assess the health of their blood vessels. The biomarkers

The main aim of the present study was to assess the dietary intake of Spanish recreational cyclists and triathletes. The main finding was that a large proportion of the present sample consumed an unbalanced diet, characterised by excess protein, and CHO and vitamin E deficiencies. Females and triathletes appear to follow a healthier diet than

Since the National Institute on Aging and Alzheimer’s Association published its 2011 guidelines detailing distinct diagnostic recommendations for preclinical, mild cognitive impairment and dementia stages, research geared towards Alzheimer’s disease (AD) research has progressed. As a neurodegenerative syndrome, diagnosis originally depended on the clinical picture, MRIs and cognitive testing. However, more recently, this exceptionally complex

NORTH CHICAGO, Ill., July 25, 2021 /PRNewswire/ — Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Multiple data presentations at the 2021 ASCRS (American Society

As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus. Vaccines against COVID-19, which were developed based on the chemistry and genetic code of this initial virus, may confer less

1. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116:2062–72. CAS  PubMed  PubMed Central  Article  Google Scholar  2. Muscogiuri G. Vitamin D: past, present and future perspectives in the prevention of chronic diseases. Eur J Clin Nutr. 2018;72:1221–5. PubMed  Article  Google Scholar  3. Autier P, Boniol M, Pizot C, Mullie P.

Whilst not typically considered for the shortlist for previous trials, Africa is an emergent continent based on its size, demographics, level of economic growth and commitment to improving healthcare and life expectancy. Presently, the population of the African continent is made up of over 1.34 billion people and it is anticipated this will rise to

SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) — BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that an article summarizing the scientific rationale for the Company’s upcoming pivotal Phase 3 Trial of its NE3107 asset in Alzheimer’s disease has been

In the evolving field of cancer biology and treatment, innovations in organ-on-a-chip microdevices allow researchers to discover more about the disease outside the human body. These organs-on-chips serve as a model of the state an actual cancer patient is in, thus allowing an opportunity to finding the correct treatment before administering it to the patient.

1. Kumar J. Epidemiology of hypertension. Clin Queries: Nephrol. 2013;2:56–61. Article  Google Scholar  2. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285–92. CAS  Article  Google Scholar  3. Matsumoto K, Jin Z, Homma S, Elkind MS, Rundek T, Mannina C, et al. Association between central blood pressure and subclinical cerebrovascular disease in

Advancements in precision medicine offer the potential to transform healthcare and create customized medical solutions for patients. Mario Papillon, CEO of Cerba Research, discusses how his organization is supporting patients and helping them receive unique treatments more quickly by delivering efficient clinical trials. This dynamic approach, in combination with worldwide access to industry-leading laboratories, has

Issued: London UK – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for patients with anaemia due to chronic kidney disease (CKD). The ASCEND programme showed that daprodustat met its primary efficacy

Clinical trials are vital and ongoing, particularly during the current pandemic. However, the risk from variants remains a concern. A number of clinical pathologists from Cerba Laboratory recently presented some approaches on how to manage SARS CoV 2 variants during the clinical trial process. Dr. Benedicte Roquebert is based in the microbiology department of Cerba

The present analyses included 90 national surveys from LMIC’s carried out between 2010 and 2019 (median year = 2014). Countries included in the analyses represented 87.1% of all low-income countries in the world as of 2014, 70.6% of all lower-middle and 50.9% of all upper-middle-income countries. Supplementary Table 1 shows the numbers of children in each income

Whilst pandemics are thankfully not common; COVID-19 has brought with it a profound global impact. By June 2020, global deaths had reached 420,000 whilst over 7.5 million people had been infected. As increased optimism surrounded the control of the virus, the impact on life is still to be fully understood. Some forecasts predict grim long-term

BOSTON–(BUSINESS WIRE)–Jul. 19, 2021– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the selective NaV1.8 inhibitor VX-548 and that it expects to commence a second Phase 2 study in acute pain following abdominoplasty surgery in the coming weeks. “Based on the favorable

For more than 30 years, scientists on the U.N.’s Intergovernmental Panel on Climate Change have focused on human-induced climate change. Their fifth assessment report led to the Paris Agreement in 2015 and, shortly after, a special report on the danger of global warming exceeding 1.5 degrees Celsius above pre-industrial levels. The Nobel Prize-winning team stressed

The CGM, food intake data, Internet of Things technology, and machine learning algorithms in the Twin Precision Treatment Program optimized combinations of nutrients and provided nutritional guidance to type 2 diabetes patients that helped them consume foods that do not produce glucose spikes and avoid foods that cause blood glucose spikes. The program participants in

CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ – Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final results from the Phase 2 ANT-005 study with its novel investigational anticoagulant abelacimab. Published today in the New England Journal of Medicine,1 and simultaneously presented as a late breaker at the International Society of Thrombosis and

The ongoing coronavirus disease pandemic 2019 (COVID-19), which is caused by a novel betacoronavirus – namely the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) –  has led to immense disruptions to public health and economic wellbeing worldwide. Scientists have developed COVID-19 vaccines at a record speed, and several of these have received emergency use approval

1. Volkert D, Beck AM, Cederholm T, Cereda E, Cruz-Jentoft A, Goisser S, et al. Management of Malnutrition in Older Patients-Current Approaches, Evidence and Open Questions. J Clin Med. 2019;8:974–90. https://doi.org/10.3390/jcm8070974. 2. Avila-Carrasco L, Pavone MA, González E, Aguilera-Baca Á, Selgas R, Del Peso G, et al. Abnormalities in Glucose Metabolism, Appetite-Related Peptide Release, and

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 17, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) today announced new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrate that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high